Breast cancer patients to benefit from new NHS treatment.

The guidance approves ribociclib (brand name Kisqali), made by Novartis, combined with an aromatase inhibitor as an additional treatment option for hormone receptor-positive, HER2-negative early breast cancer that has responded to initial treatments, including surgery, but where there is a higher risk of the cancer returning. 

The approval means ribociclib becomes the 25th out of 26 breast cancer treatments that NICE has recommended for NHS use in the last seven years. 

This is fantastic news for the tens of thousands of patients and their loved ones who are now benefiting from access to cutting edge new treatments.

It is also due in no small part to the willingness of companies to engage with us constructively, as in the case with ribociclib, to ensure the benefits of their treatments are properly presented and appropriately priced. 

Helen Knight, director of medicines evaluation at NICE

Read the full story on the new breast cancer treatment from NICE